In the BioHarmony Drug Report Database

"Preview" Icon

Larotrectinib

Vitrakvi (larotrectinib) is a small molecule pharmaceutical. Larotrectinib was first approved as Vitrakvi on 2018-11-26. It is used to treat neoplasm drug resistance and neoplasm metastasis in the USA. It has been approved in Europe to treat abdominal neoplasms. It is known to target high affinity nerve growth factor receptor. Vitrakvi’s patents are valid until 2037-04-04 (FDA).

 

Trade Name

 

Vitrakvi
 

Common Name

 

larotrectinib
 

ChEMBL ID

 

CHEMBL3889654
 

Indication

 

abdominal neoplasms, neoplasm drug resistance, neoplasm metastasis
 

Drug Class

 

Tyrosine kinase inhibitors: tropomyosin receptor kinase (TRK) inhibitors

Image (chem structure or protein)

Larotrectinib structure rendering